

Barcelona, Spain

Pre-Symposium 6

Thyroid Committee / European Society of Endocrine Surgeons (ESES)

Saturday, October 12, 13:00 - 16:00

Session Title

An Update on differentiated thyroid cancer (DTC): Overview of Management

Chairpersons

Slimane Zerdoud (Toulouse, France)

Anca Avram (Michigan, United States of America)

Programme

13:00 - 13:25 Frederic Sebag (Marseille, France / ESES): Surgical Strategy at Initial Diagnosis

13:25 - 13:50 Elif Hindie (Bordeaux, France): Strategies and Concepts Regarding Post-Surgery Radioiodine Treatment of DTC

13:50 - 14:15 Luca Giovanella (Lugano, Switzerland): Multiscale Prognostic Factors for the Management of DTC

14:15 - 14:45 Coffee Break

14:45 - 15:10 Markus Luster (Marburg, Germany): Radioiodine Treatment for Metastatic DTC: - How Much? How Many? How Often?

15:10 - 15:35 Sophie Leboulleux (Villejuif, France): Redifferentiation of Radioiodine Refractory DTC

15:35 - 16:00 Discussion

Educational Objectives

1. Discuss surgical management: total thyroidectomy versus lobectomy
2. Bring elements of discussion and reflection on the appropriate tools to the decision-making process of the choice of treatment with iodine 131
3. To envisage the future on the possibilities of redifferentiation of the iodo refractory diseases

Summary

The management of thyroid cancer is evolving in all parts of its management, from initial treatment to treatment of metastases. This symposium proposes to discuss all these trends and calls on experts in the different fields to take stock of the evolution of practices and to give trends for the years to come. The goal is to promote the best care for patients and to offer the best treatment for the right patient.

Key Words

Thyroid Cancer, Surgery, Iodine 131, redifferentiation